Angiogenic and Tissue Remodeling Factors in the Prostate of Elderly Rats Submitted to Hormonal Replacement

Abstract

The influence of senescence and hormone replacement on the onset of pathologic processes in the prostate is not yet fully understood. The aim was to identify the immunoreactivity and protein levels of molecules involved in cell proliferation, tissue remodeling and angiogenesis in the ventral prostate of elderly rodents following hormonal replacement. Male Sprague-Dawley rats were separated into one Young group (4-months old), treated with peanut oil (5 mL kg 21 , s.c.), and six Senile groups. The senile rats (10-months old) were subdivided into: Senile group (SEN) (5 mL kg 21 peanut oil, s.c.); Testosterone group (TEST) (5 mg kg 21 testosterone cipionate, s.c.); Estrogen group (EST) (25 mg kg 21 17b-estradiol, s.c.); castrated group (CAS) (surgical castration); castrated-testosterone group (CT) (same treatment as CAS and TEST groups); and castrated-estrogen group (CE) (same treatment as CAS and EST groups). After 30 days, samples of the ventral prostate were harvested for analyses of insulin-like growth factor-1 receptor (IGFR-1), matrix metalloproteinase-9 (MMP-9), vascular endothelial growth factor (VEGF) and endostatin features. IGFR-1 and MMP-9 showed increased protein levels and epithelial immunolabeling both after hormonal replacement and castration. Increased VEGF levels and reduced endostatin were verified in the SEN group. Hormonal therapy and castration led to a higher increase of VEGF, especially in the EST, CAS, and CE groups. Endostatin increased mainly in the TEST and CT groups. Hormonal therapy in senescence generated a reactive microenvironment characterized by the increase of mitogenic and tissue remodeling factors and by the imbalance of angiogenesis, which possibly compromised organ function and predisposed toward glandular disorders.

Prostatic angiogenic responses in late life: Antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model

“…This life period is associated with significant hormonal changes in the prostate, characterized by progressive estradiol accumulation and a simultaneous decrease of androgen levels as well as reduced prostatic sensitivity to androgenic actions . Several studies have demonstrated structural and paracrine signaling alterations in the prostate during late life due to hormonal imbalance . Accordingly, Hetzl et al reported that the enhancement of this imbalance by promoting hormonal ablation led to increased fibroblast growth factor (FGF) signaling in the prostatic microenvironment of aged rats, pointing to a possible androgen‐independent FGF activation.…”

In touch with your feminine side: how oestrogen metabolism impacts prostate cancer

“…In the prostate, androgens are required for normal development and function. However, the role of oestrogens in normal prostate development is ill defined, as biochemical mechanisms are still under investigation; the current dogma being that oestrogens are involved in the differentiation of epithelial tissue (Chen et al 2012, Francis et al 2013) and regulation of prostatic angiogenesis (Montico et al 2013).…”

Differential tempol effects in prostatic cancer: angiogenesis and short- and long-term treatments

“…These molecules can be secreted by the tumor and/or stromal cells, or mobilized from the extracellular matrix (Tuxhorn et al, 2001;Van Moorselaar and Voest, 2002;Condon, 2005). The vascular endothelial growth factor (VEGF), which is considered the most potent mediator of angiogenesis and endothelial cell functions, stimulates endothelial cell proliferation, differentiation and migration, and promotes increased vascular permeability (Van Moorselaar and Voest, 2002;Montico et al, 2013;Li et al, 2023).…”